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Abstract
Perivascularly implantated matrix embedded endothelial cells (MEECs) are potent regulators of 
inflammation and intimal hyperplasia following vascular injuries. ECs in porous collagen scaffolds 
adopt a reparative phenotype with significant therapeutic potential. Although the biological effects 
of MEECs are increasingly understood, less work has studied the tuning of scaffold properties to 
control cell-substrate interactions and subsequent biological outcomes. We hypothesized that 
modulating scaffold degradation would change EC phenotype. Scaffolds with differential 
degradation rates were prepared by crosslinking and pre-degradation. Vascular injury increased 
degradation and the presence of MEECs retarded injury-mediated degradation. MEECs responded 
to differential scaffold properties with altered cell viability in vivo, suppression of smooth muscle 
cell (SMC) proliferation in vitro, and changes in IL-6 and MMP-9 expression. When implanted 
perivascularly to a murine carotid wire injury model, tuned scaffolds changed MEEC effects on 
vascular repair and inflammation. Live animal imaging allowed for real-time tracking of cell 
viability, inflammation, and scaffold degradation in vivo, affording an unprecedented 
understanding of interactions between cells, substrate, and tissue. MEEC-treated injuries exhibited 
improved endothelialization and reduced SMC hyperplasia over 14 days. These data demonstrate 
the potent role material design plays in tuning MEEC efficacy in vivo, with implications for the 
design of clinical therapies.
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1. Introduction
Cellular therapeutics have been increasingly proposed to treat vascular injuries and sustain 
the impact of vascular interventions[1]. Endothelial cells (ECs) are regulators of every aspect 
of vascular biology and when embedded in a matrix can be maintained in a stable regulatory 
phenotype that has profound effects on vascular repair[2, 3]. Injection of cells without the 
supporting matrix elicits a significant immune reaction, which is obviated by embedding 
them in a scaffold. Matrix embedded ECs mimic the secretome of healthy, confluent 
endothelium in contrast to the secretome of sub-confluent ECs, which can promote disease 
processes[4]. This regulatory and reparative phenotype is modulated by culture on 3D as 
opposed to 2D scaffolds[5]. As the endothelial cell secretion profile is modulated by many 
parameters, embedding endothelial cells within 3D porous polymeric scaffolds stabilizes 
endothelial cells phenotype by controlling cell-substratum interactions. These matrix 
embedded endothelial cells (MEECs) have potent effects on regulating the response to 
vascular injury. Scaffold architecture, cytoskeletal rearrangement and mechanical properties 
control cell signaling and production of inflammation-modulating cytokines released by 
these endothelial cells[5, 6, 7]. The unique cascade of events during vascular repair – 
including inflammation, cellular infiltration, thrombosis, and smooth muscle cell 
proliferation – precludes a ‘one size fits all’ approach to material design, and requires that 
cell-biomaterial therapeutics be tested in a clinically relevant context[3, 8]. Degradable 
materials offer the opportunity for a greater level of control over cell-material interactions 
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and insight into dynamic environments. As materials degrade, their physicochemical 
properties evolve, changing embedded cell behavior and the surrounding tissue state. This 
can be exploited to control the evolving tissue state and enhance the therapeutic effects of 
material-cell interactions. Tuning the scaffold degradation rate is often tied to changes in 
other physicochemical properties of materials including elastic modulus, surface chemistry 
and ligand density, and porosity. Evaluating how this complex milieu changes in tandem 
with cell functionality can provide crucial insights into the tripartite relationship between 
cells, substrate, and the tissue microenvironment
In this study, we modified compressed collagen matrices to exhibit a range of material 
degradation kinetics, from ‘fast-degrading’ scaffolds that degrade completely in two weeks 
to moderate or highly crosslinked ‘slow-degrading’ scaffolds that only lose ~50% of mass 
over the same period in vivo. We then used these differentially degrading scaffolds to 
explore embedded cell behavior in vitro and in vivo. Using in vivo imaging technologies, we 
performed real-time, noninvasive tracking of material degradation, cell viability, and local 
inflammation [9], and used these data to understand the relationships between material fate, 
cell viability and healing capacity. We found that degradation rate of scaffolds in vitro and in 
vivo was dependent on disease state and cellularity. Vascular injury increased degradation 
and the presence of cells retarded injury-mediated degradation and further stabilized 
matrices, possibly due to changes in local inflammation-driven proteolysis. ECs in 
degradation-tuned scaffolds were able to differentially inhibit SMC proliferation and had 
altered IL-6 and MMP-9 expression, though most of their biosecretory profiles were 
unchanged. Finally, we demonstrated treatment with MEECs improved endothelialization 
and reduced SMC hyperplasia and inflammation in a mouse carotid wire injury model. 
Conclusions drawn from this study will improve our understanding of the role cell-substrate 
interactions play in endothelial cell biology. More broadly, they should inform the design of 
biomaterial carriers for cell therapies.
2. Results
2.1. Control of compressed collagen scaffold degradation in vitro and in vivo is dependent 
on disease state and ECs
We created a family of materials with a range of degradation kinetics and properties by 
variably crosslinking or pre-degrading compressed collagen scaffolds. Scaffold degradation 
varied when immersed without cells in growth media for 10 days (to mimic the in vitro cell 
seeding period prior to in vivo implantation), followed by 5 days in collagenase-containing 
media (to mimic exposure to endogenous proteases following in vivo implantation) (Figure 
1A). Slow, standard and fast degrading matrices lost 10, 30 and 40%, respectively, of their 
mass over 10 days. While collagenase had no impact on the slow degrading materials, 
degradation of standard matrices increased substantially and fast degrading matrices were 
essentially obliterated (Figure 1A). Cell-seeded scaffolds implanted perivascular to the 
injured murine carotid artery demonstrated similar trends to in vitro degradation (Figure 
1B). Injury increased degradation and the presence of cells retarded injury-mediated 
degradation and further stabilized matrices (Figure 1C), possibly due to increased local 
inflammation-mediated proteolysis. Cell viability and scaffold degradation were followed 
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using in vivo imaging. All ECs were lost 8 days after implantation but viability doubled in 
the slow degrading devices (p < 0.05, Figure 1D). Assuming that cell viability numbers 
below 10% were negligible in efficacy, we correlated effective cell viability with remaining 
material mass. Across all three material types, we observed a strong linear correlation, 
suggesting cell viability was tightly connected with the remaining scaffold mass (Figure 1E).
2.2. Differentially degrading scaffolds support cell engraftment and proliferation
Despite differences in pore size (Figure 2A–B) and mechanical properties (Figure 2C) we 
ensured that all scaffolds bore the same number of ECs at baseline (Figure 2 D–E), and prior 
to implantation (Figure S1). Increasing mechanical modulus was associated with a decrease 
in pore size (Figure S2), which was correlated with an increase in cell viability in vivo 
(Figure 1D), but no change in cell number in vitro (Figure S1). Image analysis of cell area of 
embedded ECs in different scaffolds showed no statistically significant change in cell 
morphology across scaffold conditions (Figure 1E, p > 0.05).
We assessed the in vitro capacity of MEECs cultured on differentially degrading scaffolds to 
inhibit human aortic smooth muscle cell (HASMC) proliferation as a model of the 
therapeutic effects of MEECs in vivo. Devices all significantly inhibited HASMC 
proliferation in a manner correlated with degradation rate (p < 0.05, cf. controls and each 
other) (Figure 3A). MEECs in slow-degrading scaffolds expressed detectable levels of 
matrix metalloproteinase-9 (MMP-9) while standard and fast-degrading scaffolds did not (p 
< 0.05). As MMP-9 can readily degrade denatured collagen, this may be indicative of a cell-
mediated remodeling of the matrix itself. This remodeling may be driven by the higher 
stiffness of slow-degrading scaffolds. Additionally, MEECS in fast-degrading scaffolds 
expressed lower levels of interleukin-6 (IL-6), a potent cytokine involved in regulating the 
inflammatory response to vascular injury (p < 0.05, significance between fast-degrading 
scaffolds and other treatment conditions). Although MEECs in native and slow-degrading 
scaffolds expressed significantly higher levels of PECAM-1 than fast-degrading scaffolds (p 
< 0.05, fast-degrading versus other conditions), the levels were near the detection limit of the 
assay and were not judged to be meaningful. Remarkably, MEECs in different scaffolds did 
not show any significant differences in expression across the remaining range of 
inflammatory and ECM-modifying proteins tested (Figure 3B).
2.3. Improved endothelialization and reduced SMC hyperplasia and inflammation in MEEC-
treated vascular injury
We hypothesized that the observed in vitro reduction in SMC proliferation and changes in 
MEEC secretome could result in functional improvements in vascular structure subsequent 
to injury. During wire injury, mouse carotids were denuded of endothelial cells, and an early 
inflammatory response was detected. By five days, smooth muscle cell hyperplasia was 
evident along with continued inflammation and only modest endothelial recovery. After 14 
days, the vessel response had matured but remained diseased with a sustained intimal 
thickening. MEECs reduced inflammation at all time points, minimized SMC hyperplasia, 
and enhanced endothelialization, again in a manner dependent on matrix degradation (Figure 
4A). Treatment with acellular scaffolds or free cells did not show improvements over 
untreated controls at 14 days (Figure S3).
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Histological scoring of endothelialization and smooth muscle cell proliferation confirmed 
dependence on degradation rate. Endothelial recovery after injury was maximized for the 
slow degrading matrices and in this model there was no detectable decrease in smooth 
muscle cell proliferation except for the matrices with longest in vivo persistence (Figure 4B–
C). Notably, the fast-degrading scaffolds exhibited equal or inferior performance to injury-
only controls, possibly due to the inflammatory microenvironment causing MEECs to shift 
away from a reparative phenotype and towards a pathological one. These endothelialization 
and SMC hyperplasia results correlated with the local tissue inflammatory response detected 
after tail-vein injection of a fluorescent reporter of cathepsin B (Figure 5A). The acellular 
matrices had an insignificant effect on cathepsin B activity but cellular matrices reduced 
local vascular inflammation, with the greatest reduction for the slowest degrading devices (p 
< 0.05, Figure 5B, Figure S4). Longer-lasting scaffolds improve inflammatory modulation, 
likely through a combination of increased EC viability leading to reduced immune cell 
activation as well as modified cell-substrate interactions leading to critical changes in cell 
phenotype.
3. Discussion
Material design is known to be of paramount importance in determining the phenotype of 
endothelial cells. Embedding endothelial cells in appropriately designed biomaterial 
scaffolds causes the cells to adopt a healthy, reparative phenotype that reduces inflammation, 
immune responses, and tissue hyperplasia following a vascular injury, likely through 
paracrine effects on the surrounding tissue[4, 10, 11]. Our goal was to determine if these 
therapeutic effects of MEECs could be improved through changing the material properties. 
This study demonstrates that control over scaffold crosslinking could modulate these critical 
cell-substrate interactions and tune the reparative phenotype of matrix-embedded endothelial 
cells.
Cell behavior in 3D scaffolds has been shown to be highly dependent on surface chemistry, 
mechanical properties, pore size, and degradation rate[12, 13, 14]. Previous work on 
endothelial cells has elucidated some scaffold properties that are critical determinants of EC 
function. Extensive studies[15] have shown that mechanical stiffness of matrices have 
profound effects on the ability of ECs to form new capillary networks[16]. A series of elegant 
experiments has demonstrated that EC survival and proliferation on a fibronectin-coated 
surface is linked to a total cell area (i.e. a spread morphology) and not to ligand density, 
suggesting that matrix-induced changes in cell morphology can have significant effects on 
EC biology[14]. EC morphology and behavior has also been shown to be dependent on 
scaffold pore size, chemistry, and degradation rate[12, 17], though these effects have not been 
as well explicated. While the effects of scaffold properties on angiogenesis and EC survival 
and morphology have been studied in detail, fewer studies have focused on other aspects of 
EC function such as its immunomodulatory role and interactions with other cells. Glycation 
of collagen surfaces was shown to reduce FAK activation and NO release of ECs cultured 
under flow, and limit EC alignment during cyclic strain[18, 19]. In addition, ECs on glycated 
collagen surfaces exhibited increased permeability due to disrupted cell-cell interactions, 
which were attributed to changes in integrin binding and expression[19].
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Previously, we have shown that culture of ECs inside collagen scaffolds of varying 
mechanics has significant effects on cell functionality in vitro. Cells embedded in more 
highly crosslinked matrices were able to inhibit SMC proliferation mediated through 
increased secretion of heparin sulfate proteoglycan. Higher stiffness also led to EC-mediated 
inhibition of T cell proliferation and increased expression of MMP inhibitors[11]. These 
phenotypic changes were tied to variations in the amount though not composition of ECM 
deposition in the scaffolds and variable integrin expression. These differentially crosslinked 
scaffolds also exhibited a range of other changes in physicochemical properties, though 
these were not examined; furthermore, the study was not extended to an in vivo vascular 
repair model. We hypothesized that EC functionality in treating vascular injury in vivo could 
be tuned by changing scaffold properties.
Here, we looked directly at the role of scaffold degradation in controlling EC functionality in 
a vascular injury model in vivo. We demonstrate that slower degrading scaffolds, which 
exhibit smaller pore size and stiffer bulk mechanics but no observable changes in cell 
morphology, were able to support increased cell viability in an in vivo carotid injury animal 
model. ECs in degradation-tuned scaffolds were able to differentially inhibit SMC 
proliferation and had altered IL-6 and MMP-9 expression, though most of their biosecretory 
profiles were unchanged. When implanted in vivo, cell-laden scaffolds were able to 
attenuate the inflammatory response following vascular injury in a degradation rate 
responsive manner, with attendant changes in endothelial recovery and SMC hyperplasia. 
These data suggest a strong therapeutic role for MEECs in potentiating vascular repair that 
can be tuned through manipulation of scaffold properties. Understanding the precise 
mechanism of the in vivo response is complicated by the range of physicochemical scaffold 
properties that changed from condition to condition, including degradation rate, mechanical 
stiffness, and pore size. Based on the aforementioned literature, we believe all of these 
factors are likely important in affecting EC-substrate interactions. During the course of 
tuning scaffold properties, it is inevitable that a variety of physicochemical factors will 
change; only in highly artificial controlled studies have previous studies been able to 
separate these effects[14]. In contrast, we present here a clinically relevant method of tuning 
scaffold properties to affect cell-substrate interactions. Changes in material properties are 
characterized in detail, and the resulting phenotypic response is evaluated by real-time 
monitoring of in vivo models. These results reveal an intricate interplay of scaffold 
properties and cell phenotype influencing each other, which in turn have profound effects on 
the surrounding tissue. We hypothesize that a key determinant of the differential biological 
response was the prolonged and increased viability of embedded cells in slower-degrading 
scaffolds, evidenced by the strong correlation between remaining scaffold mass and cell 
viability. Understanding the mechanism of this effect is challenging, but we believe that the 
inflammatory in vivo injury environment is fundamentally hostile to EC survival. The 
slower-degrading scaffolds may have protected EC viability through enhanced duration of 
EC-substrate interactions, lower porosity leading to a relatively privileged cellular 
microenvironment, or changes in mechanotransduction signals leading to altered EC 
modulation of its surroundings. This increased viability enhanced the exposure time to the 
anti-inflammatory effects of MEECs, changing healing outcomes. We hypothesize that 
Unterman et al. Page 6
Adv Healthc Mater. Author manuscript; available in PMC 2016 October 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
MEECs were able to stimulate re-endothelialization of the damaged vessel, which in turn 
had potent effects on inflammation and tissue state.
Scaffold degradation rates in vivo are likely dependent on the expression of matrix 
degrading enzymes by inflammatory cells, matrix remodeling by engrafted endothelial cells, 
and mechanical stresses. This intricate interplay involves feedback loops between the 
embedded endothelial cell secretome, the level of inflammation, and the cell substrate 
interactions. Tweaking the initial cell-substrate interactions and its subsequent degradation 
rate can have significant effects on cell viability and phenotype. We hypothesize that this 
cell-mediated mechanism of slower scaffold degradation is due to modulation of the 
inflammatory tissue response following vascular injury. Previous studies have shown a 
potent effect of MEECs on inflammatory and immune responses; here, we showed that 
slower degradation kinetics, with its attendant increased cell viability, was able to further 
reduce the inflammatory response to vascular injury in vivo over 12 days. These effects 
persist even after the degradation of most of the scaffold and loss of cells; reduced 
inflammation was seen even though cell viability had largely disappeared after a week in 
vivo.
The therapeutic effect of MEECs may cause longer-term changes to the secretome of cells in 
the surrounding tissues, leaving a healthier tissue even after scaffold degradation. In vitro co-
culture of MEECs with SMCs showed significant inhibition of SMC proliferation in a 
degradation rate dependent manner. Further in vitro analysis of the matrix-embedded HAEC 
secretome suggests that the different scaffolds result in changes to cell phenotype, notably 
increasing secretion of both IL-6 and MMP-9 for slower-degrading scaffolds. The increased 
expression of IL-6 for scaffolds which demonstrated reduced inflammation in vivo and SMC 
proliferation in vitro appears initially paradoxical, given that it is normally assumed to be a 
pro-inflammatory cytokine that increases SMC growth[20]. However, recent research has 
demonstrated multiple signaling modalities for IL-6 depending on its interaction with IL-6R 
in either membrane bound or soluble form. These different modalities have been shown to 
modulate whether IL-6 signaling is pro- or anti-inflammatory, though the details have yet to 
be fully elucidated[21]. Further investigation of the expression of proteins involved in this 
modulation is necessary to help confirm its role as an anti-inflammatory cytokine in vivo. 
Similarly, the increased secretion of MMP-9 by slower degrading (and thus SMC-inhibitory) 
scaffolds hints at a complex interaction between matrix remodeling and cellular behavior. 
Previous studies have demonstrated MMP-9 to have a potent role in enhancing SMC 
proliferation and migration following vascular injury, making the correlation of its increased 
expression with reduced SMC proliferation ambiguous[22, 23]. We must also consider that 
MEECs secrete a plethora of cytokines and chemokines, many of which were not measured 
here, so MMP-9 function alone may not explain the MSC response. However, while MMP-9 
secretion by SMCs is likely important in neointima formation, it also has a significant role in 
the organization of adventitial collagen and modulation of cell-substrate interactions[23]. The 
observed increase in MMP-9 secretion may thus be tied not to SMC proliferation but rather 
to the embedded HAECs ‘tuning’ their surrounding matrix. Substrate stiffness has long been 
tied to expression of MMPs and other matrix remodeling proteins, with increasing stiffness 
often causing upregulation of MMPs[24]. Additionally, endothelial progenitor cells seeded in 
a gelatin-hyaluronan hydrogel increased MMP expression at higher stiffnesses up to 650 
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Pa[25]. Gelfoam-embedded HAECs likely upregulated MMP-9 activity in response to the 
higher substrate stiffness of the crosslinked, slow-degrading matrix. These changes in the 
HAEC secretome in differentially degrading scaffolds hint at a multifaceted interaction of 
factors controlled by cell-substrate interactions that can modulate their reparative phenotype. 
In this study, we used a mouse carotid wire injury model as a method of mimicking intimal 
lesions in the vascular endothelium common following vascular interventions such as 
stenting. This model was particularly well suited to evaluating EC-material interactions in 
potentiating vascular repair. Using a small animal model allowed us to noninvasively track 
material degradation, tissue inflammation, and cell viability in real time using IVIS, offering 
an unprecedented opportunity to obtain spatial and temporal resolution in studying cell-
material-tissue interactions. The type of injury created by wire denudation of the epithelium 
matched expected injuries following stenting, with the attendant inflammation, SMC 
hyperplasia, and re-endothelialization over time[26]. Limitations of this model, however, 
include the relatively rapid re-endothelialization of untreated controls (which does not occur 
in rat balloon injury models) and the relatively minor insult to the media, potentially 
decreasing the SMC response. Nevertheless, it allowed us to probe the acute response to 
vascular injury and its remediation by MEECs as a function of degradation rate.
4. Conclusion
Matrix-embedded endothelial cells have been previously described as a promising 
therapeutic method to reduce inflammation and intimal hyperplasia following vascular 
injury. Here, we focused on the role of material design in tuning the therapeutic effect of 
MEECs. We demonstrate that cell-substrate interactions can be controlled by varying the 
crosslinking (and hence degradation rate, mechanics, and pore size) of standard compressed 
collagen scaffolds. Using a novel mouse carotid wire injury model and sophisticated in vivo 
imaging techniques, we were able to track scaffold degradation, cell viability, and local 
inflammation in real time. Control of compressed collagen scaffold degradation in vitro and 
in vivo was dependent on disease state and ECs. Vascular injury increased degradation and 
the presence of cells retarded degradation and further stabilized matrices. Slower-degrading 
scaffolds were shown to reduce SMC proliferation in vitro, protect against loss of cell 
viability in vivo, reduce injury-related inflammation in vivo and improve endothelialization 
and SMC hyperplasia. This is likely the result of changes in the scaffold mechanics and 
degradation rate that modulated the endothelial cell secretome, especially that of IL-6 and 
MMP-9. These data demonstrate that material properties can be controlled to tune the 
reparative outcomes of cell-based therapeutics.
5. Experimental Section
Synthesis of scaffolds with differential degradation rates
Standard scaffolds (Gelfoam compressed sponge, Pfizer) were cut to 2×4×6 mm blocks and 
used as received. To create slow-degrading matrices, standard blocks were chemically 
crosslinked using carbodiimide chemistry. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
(EDC, Sigma) was dissolved at 54 mM in phosphate buffered saline (PBS, Lonza) with 22 
mM N-hydroxysuccinimide (NHS, Sigma). This EDC/NHS crosslinker solution was added 
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to blocks (10 ml of crosslinker solution for 5 scaffolds) and agitated for three hours at room 
temperature, forming amide bond crosslinks within the material. Following crosslinking, 
slow-degrading matrices were thoroughly washed in PBS and stored in Endothelial Growth 
Medium-2 (EGM-2, Lonza) overnight before use. Fast-degrading scaffolds were produced 
by partial enzymatic degradation of standard matrices. A range of collagenase type 4 
(Worthington Biochemical) concentrations in PBS (0.001 mg/ml, 0.01 mg/ml, 0.1 mg/ml, 
and 1 mg/ml) were prepared and added to scaffolds incubated at 37° C (90% humidity, 5% 
CO2) for periods ranging from 10 to 60 minutes. Subsequently, scaffolds were thoroughly 
washed in PBS and stored overnight in EGM-2 media prior to use.
In vitro mechanical analysis of scaffolds
Scaffolds with different degradation kinetics were cut to 9×8×2 mm blocks, measured by 
digital micrometers, and placed in an Instron E3000 uniaxial mechanical tester between two 
unlubricated, nonporous compression platens. An unconfined compression test was 
performed at 0.5%/s until 20% strain; scaffolds were immersed in PBS throughout the test to 
mimic implantation conditions. The resultant normal force was measured using a 10 N load 
cell (Instron). Engineering stress in the normal direction and axial strain were calculated 
based on initial material geometry, using an assumption of constant cross-sectional area. 
Compressive modulus was calculated from the linear portion of the stress-strain curve, 
approximately 5–20% strain.
In vitro degradation kinetics
Matrix blocks were labeled with fluorescent tags to enable degradation tracking in vitro and 
in vivo. A succinimidyl ester of Texas Red-X (Invitrogen) was dissolved in dimethyl 
sulfoxide to 10 mg/ml. Each block was immersed in 320 μl of 200 mM sodium bicarbonate 
to which 0.93 μl of Texas Red X concentrate was added. The reaction proceeded at room 
temperature for 1 hour, after which scaffolds were washed thoroughly in PBS to remove 
unreacted fluorophore. Scaffolds were incubated in EGM-2 supplemented media for ten 
days changed daily and assessed for fluorescent signal on a Varioskan Flash fluorescent 
plate reader (excitation filter: 605 nm, emission filter: 660 nm, Thermo Scientific). After ten 
days, in vivo implantation was simulated by the addition of 30 μl of a 0.25 μg/l collagenase 
solution for an additional five days. It was determined that a single fast-degrading matrix 
condition (0.01 mg/ml collagenase reacted for 1 hour) exhibited similar cell number to 
native and slow-degrading scaffolds for the entire 10 days of pre-implantation cell culture 
and this condition was chosen for all further experiments (Figure S1).
Cell seeding onto scaffolds
Human aortic endothelial cells (HAECs) isolated and pooled from healthy 20–25 year old 
adult donors (Promocell) were maintained at 37° C in 90% humidity and 5% CO2 and 
cultured for up to 6 passages in Endothelial Growth Medium 2 (EGM-2, Lonza) 
supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin (Lonza). 
Prior to cell seeding, all matrix formulations were tagged with Texas Red-X and incubated 
in 5 ml EGM-2 supplemented media overnight. Each scaffold was seeded with 105 cells by 
applying a 20 μl suspension of 5×104 HAECs to either side of the scaffold[7]. After seeding, 
scaffolds were incubated at 37° C and the cells were allowed to infiltrate and adhere for 1 
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hour. Groups of three cell-seeded matrices were placed in a freestanding centrifuge tube 
containing 5 ml of EGM-2 supplemented media and incubated for 10 days. Growth medium 
was changed every 48 hours and after 10 days, scaffolds were fully degraded by digestion in 
varying concentrations of collagenase for 1 hour (1 mg/ml for fast-degrading and standard 
matrices, 4 mg/ml for crosslinked slow-degrading devices). Cell number was determined at 
periodic intervals using a hemacytometer and viability by trypan blue exclusion under 
microscopy.
Secretion of inflammation-modulating cytokines and matrix remodeling proteins by MEECs 
was evaluated using a protein expression array. Cell-laden scaffolds were incubated for 10 
days in EGM-2 supplemented media to reach maximal cell number, with media changes 
every 2 days. Following the 10 day incubation, 8 scaffolds of each type were incubated in 
1.5 ml of EGM-2 supplemented media in freestanding tubes for 48 hours. Subsequently, the 
tubes were centrifuged and the conditioned media were collected and analyzed using the 
RayBio Human Angiogenesis Antibody Array C series 1000 protein array, which tests for a 
variety of vascular-related inflammatory and matrix remodeling proteins. EGM-2 
supplemented medium was used as a negative control.
Engineering HAECs for in vivo cell tracking
In vivo cell tracking of HAECs was accomplished by transduction with the pMMP-LucNeo 
retrovirus using Polybrene at 8 ug/ml as previously described[27]. Cells expressing luciferase 
were selected for by growth in media containing G418 500 ug/ml. Luminescence 
measurements in vitro (Varioskan Flash plate reader) and following implantation in vivo 
(IVIS Spectrum) were confirmed to be linearly correlated with cell number as determined by 
hemacytometry of cells from degraded matrices.
In vitro smooth muscle cell inhibition assay
Human aortic smooth muscle cells (HASMCs) were seeded on 6-well plates (104 cells/well) 
and then exposed to HAECs seeded on fast, native, and slow-degrading matrices in 
Transwell inserts (0.4 μm pores, Corning). The ECs had been cultured in EGM-2 
supplemented media for nine days. EGM-2 supplemented media (1.5 ml) and 8 HAEC-
embedded scaffolds were added to each insert. To mimic in vivo degradation, 100 μl of 0.1 
mg/ml collagenase was applied to each well daily. On the desired day following the 
commencement of co-culture (4 and 7 days), the HASMCs were counted and compared to 
controls without co-culture.
Wire injury model and in vivo implantation of scaffolds
All animal procedures were approved by the Committee on Animal Care at the 
Massachusetts Institute of Technology (protocol #0412-032-15) and follow the National 
Institutes of Health guidelines for animal care. SKH-1 hairless male mice (Charles River) 
were used at 6 weeks of age; the strain is euthymic and immunocompetent, and was chosen 
to improve in vivo imaging of fluorescent implants. The right carotid artery was isolated, 
clamped, and a small incision was made on the internal carotid. A 0.01 inch diameter 
guidewire (SilverSpeed hydrophilic guidewire, Covidien) was inserted and retracted thrice to 
denude the endothelial layer of the artery. The incision was closed and single scaffolds were 
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gently placed around the injured vessel. A video of the carotid wire injury model can be seen 
in Figure S5. Conditions included HAEC-seeded scaffolds with different degradation rates 
(n=22 animals, 8 fast-degrading, 6 standard, 8 slow-degrading), acellular scaffolds (n=23 
animals, 8 fast-degrading, 7 standard, 8 slow-degrading), free HAECs (n=7 animals), and 
injury alone without cells or matrices (n=6 animals). Additionally, the differentially 
degrading scaffolds were placed perivascularly to healthy right carotid arteries for non-
injured controls (n=25 animals, 9 fast-degrading, 7 standard, 9 fast-degrading).
In vivo tracking
Periodic imaging of devices with Texas-Red labelled matrices and luciferase-expressing 
HAECs in intact animals providing continuous signal of matrix fate was performed with an 
In Vivo Imaging System (IVIS Spectrum, Perkin Elmer). An excitation filter of 605 nm and 
an emission filter of 660 nm was used for the former and intraperitoneal injection of 
luciferin solution (30 mg/ml Perkin Elmer) 15 minutes prior to imaging for the latter. The 
inflammatory response to injury was measured in vivo using Cathepsin B 680 FAST (Perkin 
Elmer) injected IV (100 ul PBS, 24 nmol). This dye is composed of a pair of quenched 
fluorophores separated by a Cathepsin B-sensitive peptide and only fluoresces upon 
cleavage of this linker peptide by Cathepsin B. Twenty hours after injection, the mice were 
imaged using IVIS (excitation: 675 nm, emission: 720 nm) to determine localization and 
extent of cathepsin B activity every four days.
Histological analysis
Two weeks after surgery, mice were euthanized and perfused via the left ventricle with 4% 
paraformaldehyde following a saline flush. Carotid arteries were excised with any remaining 
scaffold material and fixed in 5 ml of 4% PFA at 4 C. The injured vessel area was extracted, 
paraffin-embedded, sectioned to 5 μm from the proximal, middle, and distal elements and 
stained with VerHoeff’s elastin stain and H&E. Morphometric analysis to determine the 
degree of endothelialization was performed on all segments.
Statistics
Data are shown as mean with standard deviation. Statistical analyses were performed using 
MATLAB with ANOVA followed by a multiple comparisons procedure using the Tukey’s 
Honestly Significant Difference post-hoc test with an alpha value of 0.05. Repeated 
measures data (including material degradation, cell viability, and inflammation data) was 
analyzed in JMP statistical software. We used a mixed effects linear model with an 
autoregressive (order 1) covariance structure.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Scaffold Degradation in vitro and in vivo
Acellular scaffolds degraded in vitro differentially during culture in media for 10 days 
followed by culture in collagenase for 5 days to mimic in vivo implantation (p < 0.05, 
significant differences between all treatment levels) (A). In vivo imaging was used to detect 
fluorescently-tagged scaffolds in situ in real time demonstrating different degradation rates 
of cell-seeded scaffolds in injured mice (p < 0.05, significant differences between all 
treatment levels) (B). Upon induction of vascular injury using a carotid wire injury model, 
degradation rates of fast-degrading scaffolds without seeded cells were faster than healthy 
controls, but addition of cells slowed degradation (p < 0.05, injured acellular scaffolds vs. 
other conditions; healthy vs. cellular injured was not significant) (C). Cell viability in an 
injured perivascular environment over 9 days in vivo was assessed for each scaffold and 
compared to free cells, showing increased viability for cells in slow-degrading scaffolds (p < 
0.05, significance between slow-degrading scaffolds and all other conditions) (D). Effective 
viability (>10%) was closely correlated with remaining scaffold mass across treatment 
conditions (E).
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Figure 2. Cell-material interactions in differentially degrading scaffolds
Fluorescently tagged HAECs (green) were successfully seeded onto scaffolds, and 
proliferated over 10 days of in vitro culture (A; approximate pore boundaries outlined at 10 
days). Pore sizes of the different scaffolds varied with degradation rate (B). Scaffolds 
exhibited differential bulk mechanical properties (*, p < 0.05) (C). Z-stack images of cell-
seeded scaffolds show a relatively uniform distribution of cells throughout the scaffold (fast-
degrading scaffold shown as an example) (D); cell morphology determined by image 
analysis after seeding was not statistically different across the scaffold types (p = 0.19) (E).
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Figure 3. In vitro assessment of cell phenotype in differentially degrading scaffolds
SMC proliferation was inhibited by MEECs in a degradation-rate dependent manner (p < 
0.05, differences between all scaffold conditions and controls) (A). MEEC secretion of 
MMP-9 and IL-6 was significantly different, while other biosecretory proteins were 
unchanged (*, p < 0.05; effective detection threshold of 30% at dashed line) (B).
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Figure 4. Functional outcomes of in vivo implantation of cell-seeded devices
H&E images of murine carotid arteries 0, 5 and 14 days after intervention (A). 
Quantification of endothelial recovery (B) and SMC proliferation (C).
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Figure 5. Modulation of inflammation in vivo
Inflammation following vascular injury was tracked using a cathepsin B-sensitive 
fluorescent dye (A). Slower degrading cellular scaffolds showed significant decreases in 
inflammation over 12 days relative to post-injury inflammation (p < 0.05, significance 
between slow scaffolds and controls, free cells, and fast-degrading; significance between 
standard scaffolds and controls at this power level) (B). Collagen matrix-embedded 
endothelial cells are a potent modulator of the healing blood vessel following injury. 
Varying scaffold degradation rates and other material properties can have significant effects 
on cell viability and therapeutic function in vivo. Real time tracking of local inflammation, 
cell viability, and material degradation in vivo allows an unprecedented window into the 
dynamics of cell-scaffold-microenvironment interactions.
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